| Basics |
NanoViricides Inc.
Nanoviricides Inc is a development stage nano-biopharmaceutical company. Its business activities are to discover, develop and commercialize therapeutics to take care of patients suffering from life-threatening viral infections.
|
| IPO Date: |
July 5, 2005 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$27.48M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.12 | 4.27%
|
| Avg Daily Range (30 D): |
$0.05 | 3.39%
|
| Avg Daily Range (90 D): |
$0.05 | 3.73%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.36M |
| Avg Daily Volume (30 D): |
.15M |
| Avg Daily Volume (90 D): |
.17M |
| Trade Size |
| Avg Trade Size (Sh.): |
242 |
| Avg Trade Size (Sh.) (30 D): |
325 |
| Avg Trade Size (Sh.) (90 D): |
337 |
| Institutional Trades |
| Total Inst.Trades: |
29 |
| Avg Inst. Trade: |
$1.55M |
| Avg Inst. Trade (30 D): |
$M |
| Avg Inst. Trade (90 D): |
$M |
| Avg Inst. Trade Volume: |
.11M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.71M |
| Avg Closing Trade (30 D): |
$M |
| Avg Closing Trade (90 D): |
$M |
| Avg Closing Volume: |
76.29K |
|
|
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-.69
|
$-.14
|
|
|
Diluted EPS
|
$-.69
|
$-.14
|
|
|
Revenue
|
$ M
|
$ M
|
$
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -9.73M
|
$ -2.22M
|
$ -2.03M
|
|
Operating Income / Loss
|
$ -9.87M
|
$ -2.25M
|
$
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -5.61M
|
$
|
$
|
|
PE Ratio
|
|
|
|
| Splits |
|
Sep 24, 2019:
1:20
|
|
Sep 10, 2013:
2:7
|
|
